

THIS DOPING CONTROL SERVICES MASTER AGREEMENT (the "Master Agreement" or the "Agreement"), entered into effective as of March 11, 2015, is by and between the United States Anti-Doping Agency ("USADA"), a Colorado nonprofit corporation, located at 5555 Tech Center Drive, Suite 200, Colorado Springs, Colorado 80919, Floyd Mayweather ("Mayweather") and Manny Pacquiao ("Pacquiao"), with their principal addresses and points of contact listed in paragraph 31 of this Master Agreement. This Master Agreement includes all annexes referred to herein and attached hereto as if fully set forth in the below text.

WHEREAS USADA is the independent, non-governmental drug testing agency for the Olympic and Paralympic Movement in the United States and regularly provides sports drug testing services on a fee for services basis;

WHEREAS USADA provides specialist services and personnel to undertake independent sample collection and related administrative services for sport organizations, and has skill, knowledge and experience in that field;

WHEREAS Mayweather and Pacquiao agree to engage in a boxing competition to occur on or about May 2, 2015, at the MGM Grand Garden Arena in Las Vegas, Nevada, United States of America (the "Competition"); and

WHEREAS in order to implement quality doping controls, Mayweather and Pacquiao wish to contract USADA as an independent organization to provide services for sample collection, drug testing, Results Management Services (as defined below) and related administrative services (collectively, the "Doping Control Services") during the period from March 11, 2015 through the Competition (the "Testing Period") and for any such longer period as may be necessary to complete follow up testing analysis of samples, reporting of samples per this agreement, establishment of a review board, communication of findings, and any requested hearing (collectively, the "Results Management Services") stemming from matters originating during or before the Initial Testing Period (the "Results Management Period");

NOW, THEREFORE, for the consideration hereinafter named and commitments set forth in this Master Agreement, and other good and valuable services, the receipt of which is hereby acknowledged, USADA, Mayweather and Pacquiao agree as follows:

IT IS AGREED:

- 1) Under this Master Agreement, USADA will perform the Doping Control Services as described more specifically herein and in Annexes A, B and C attached hereto. The definitions set forth in the foregoing WHEREAS clauses shall apply throughout this Agreement without need for restatement.
- 2) Mayweather and Pacquiao grant USADA the legal authority to drug test Mayweather and Pacquiao under the terms set forth in this Master Agreement and to conduct Doping Control Services and Results Management Services as specified herein. In the event an anti-doping rule violation is established as provided herein, Mayweather and Pacquiao agree to abide by the sanctions determined through the Results Management Procedures (as defined below)

PAK

3/11/15
OK

provided for in this Agreement. This obligation shall survive the termination of this agreement.

Pre-Testing Submissions and Education

- 3) Mayweather and Pacquiao agree that on or before March 11, 2015, they shall:
- Make a required submission of a list of any medications and supplements that they have used dating back to March 1, 2015 and any medications and supplements that they may use during the Testing Period for USADA review.
 - Provide detailed schedule and whereabouts information for their regular activities, including all training times, locations, travel details and places of residence between March 11, 2015 and the Competition on May 2, 2015 ("Initial Whereabouts Filing").
 - Provide contact information for themselves and a primary athlete representative, including addresses, phone numbers and email addresses, at which they and/or their representative may be contacted by USADA.
 - Make themselves and any necessary assistants or representatives available for an in-person education meeting, unless otherwise approved by USADA, at which time the various drug testing rules and requirements to which they will be subject will be explained by representatives of USADA.

Rules

- 4) Mayweather and Pacquiao agree that Articles 1 through 10 and 24.2, and the associated definitions, of the World Anti-Doping Code (the "Code") (which may be found at <https://www.wada-ama.org/en/what-we-do/the-code>) shall be the substantive anti-doping rules for all purposes in relation to the Competition and the period of pre and post competition testing provided for in this Agreement and Annex A and that such rules shall apply directly to Mayweather and Pacquiao who consent to be bound by these rules. International Standards adopted pursuant to the Code are applicable as specified in this Agreement or otherwise provided in the Code. These provisions shall apply only to the extent they do not conflict with the terms of this Agreement. This provision shall survive termination of this Agreement.
- 5) Mayweather and Pacquiao agree that sections 5, 9-13, 16, 17(a) and 21 of the United States Anti-Doping Agency Protocol for Olympic and Paralympic Movement Testing (the "USADA Protocol") (which may be found at http://www.usada.org/wp-content/uploads/USADA_protocol.pdf) shall constitute the procedural rules applicable to any Results Management Services provided hereunder. These provisions shall apply only to the extent they do not conflict with the terms of this Agreement. This provision shall survive termination of this Agreement.
- 6) Mayweather and Pacquiao agree to submit to the jurisdiction of USADA to enforce all aspects of the Code and this Agreement in relation to them, agree to abide by any sanctions

3/1/15
JL

imposed through the Results Management Procedures set forth herein and agree that any anti-doping rule violation can be used by any other sanctioning body to prevent the violator from competing during any period of ineligibility determined through the Results Management Procedures provided for in this Agreement, including but not limited to any State Athletic Commission or Professional Boxing Federation, Association or Organization. This obligation shall survive termination of this Agreement.

Prohibited Substances and Methods

- 7) Mayweather and Pacquiao agree that the 2015 World Anti-Doping Agency ("WADA") Prohibited List (the "Prohibited List") (which may be found at <https://www.wada-ama.org/en/what-we-do/prohibited-list>) sets forth the prohibited substances and methods which will be prohibited for purposes of in-competition and out-of-competition testing and Results Management Services during the Testing Period and Results Management Period provided for in this Agreement. This provision shall survive termination of this Agreement.

Therapeutic Use Exemptions

- 8) Mayweather and Pacquiao agree that the Code and the WADA International Standard for Therapeutic Use Exemptions (the "ISTUE") (which may be found at <https://www.wada-ama.org/en/what-we-do/international-standards#TherapeuticUseExemptions>) set forth the procedures by which Mayweather and Pacquiao may apply to USADA for a therapeutic use exemption ("TUE") to use any prohibited substance or method during the Testing Period, except that USADA shall make the final determination on any application for a TUE. USADA's decision on any TUE application shall be final without any right of appeal.
- 9) Mayweather and Pacquiao agree that USADA shall notify both athletes within 24 hours of any of the following occurrences: (1) the approval by USADA of a TUE application submitted by either athlete; and/or (2) the existence of and/or any modification to an existing approved TUE. Notification pursuant to this paragraph shall consist of and be limited to: (a) the date of the application; (b) the prohibited substance(s) or method(s) for which the TUE is sought; and (c) the manner of use for the prohibited substance(s) or method(s) for which the TUE is sought. Nothing in this provision shall be construed to require the release of the underlying documentation submitted in support of any TUE application, or of any confidential medical information not explicitly included in items (a) through (c) above.

Sample Collection

- 10) USADA will comply with the WADA International Standard for Testing and Investigations ("ISTI") (which may be found at <https://www.wada-ama.org/en/resources/world-anti-doping-program/international-standard-for-testing-and-investigations-isti-0>) when collecting urine and blood samples. USADA will use test kits and doping control forms that satisfy the requirements of the ISTI and/or USADA best practices.

3/4/15



- 11) USADA will plan and implement testing subject to the terms set forth in Annex A. A brief description of the sample collection and handling process is set forth in Annex B. Mayweather and Pacquiao further agree as follows:

In-Competition Testing

- a. USADA shall conduct in-competition testing at the Competition. The in-competition testing period shall begin at the final weigh-in before the start of the Competition and shall conclude six (6) hours after the conclusion of the Competition, although any attempt to collect a sample beginning within the in-competition testing period may be concluded outside that period and shall still be considered an in-competition test.
- b. Mayweather and Pacquiao, or their designee, shall ensure that the Fight Promoter(s) grant USADA personnel access to the event venue and provide a facility for the Doping Control Station that meets the minimum requirements prescribed in the ISTI.

Out-of-Competition Testing

- c. USADA shall conduct repeated no advance notice out-of-competition testing of Mayweather and Pacquiao in accordance with USADA's best practices throughout the Testing Period. USADA shall make a good-faith effort to ensure Mayweather and Pacquiao are submitted to an equal number of such no advance notice out-of-competition tests, with the precise number of such tests left to the exclusive determination of USADA.
- d. Subsequent to submitting their Initial Whereabouts Filings, Pacquiao and Mayweather agree to continuously thereafter provide and update their whereabouts information as required by the ISTI and the USADA Whereabouts Requirements;
- e. Mayweather and Pacquiao agree that they are subject to all aspects of the ISTI and USADA Whereabouts Requirements;

Post-Competition Follow-Up Testing

- 11/c
- f. In the event that any follow-up testing is required based on samples or other information gathered during the Testing Period, USADA may collect an additional sample or samples.
- 12) USADA will make every reasonable effort to collect samples from both fighters, working with the inspectors from the appropriate State Athletic Commission to coordinate the In-Competition Testing process. However, in instances where an athlete's health and wellbeing could be adversely impacted by the sample collection process, USADA reserves the right to withdraw from testing.
- 13) USADA will be responsible for storing the samples after collection and transporting them safely and securely to a laboratory for analysis.

3/11/15
[Signature]

Sample Analysis

- 14) USADA will send all samples to a WADA-accredited laboratory ("Laboratory") for analysis.
- 15) USADA will direct the Laboratory to test the samples promptly and report the analysis of the samples in accordance with the WADA International Standard for Laboratories ("ISL"), for the presence of prohibited substances and evidence of use of prohibited methods in accordance with the 2015 WADA Prohibited List.
- 16) USADA shall maintain Sample Collection Documentation, including test results, for testing conducted under this Master Agreement for a period of ten (10) years in accordance with the WADA International Standard for the Protection of Privacy and Personal Information ("ISPPPI") (which may be found at <https://www.wada-ama.org/en/resources/data-protection/international-standard-for-the-protection-of-privacy-and-personal>). This obligation shall survive termination of this Agreement.

Notification

- 17) USADA will direct the Laboratory to report all test results promptly to USADA and WADA. USADA will report those results consistent with the terms and conditions set forth in section 11 of the USADA Protocol. A partial description of the testing procedures, as well as the analysis of samples, establishment of a review board, communication of findings, and related issues is summarized in Annex B.
- 18) Upon receipt of an adverse analytical finding from the Laboratory, USADA will promptly conduct an internal review to determine whether an applicable TUE has been granted or will be granted or if there is any apparent departure from the ISTI or ISL that caused the adverse analytical finding. If this review does not reveal an applicable previously-approved TUE or departure, USADA will communicate such finding to the athlete who provided the sample which resulted in the adverse analytical finding (the "impacted athlete"), the non-impacted athlete, the Fight Promoter(s) listed in Annex C to this Master Agreement and the appropriate State Athletic Commission(s), regardless of whether the substance is a "Specified Substance" within the meaning of Article 4.2.2 of the Code, or a prohibited substance other than a Specified Substance. Where no applicable previously approved TUE or departure is evident, USADA shall make a good-faith effort to conduct its review and report the adverse analytical finding to the impacted athlete, the non-impacted athlete, Fight Promoter(s) and appropriate State Athletic Commission(s) within twenty-four (24) hours of its receipt of such report(s) from the Laboratory. At its sole discretion, USADA may also report any adverse analytical finding to the appropriate Professional Boxing Federation, Association or Organization. In the event that an adverse analytical finding is reported to USADA, both Mayweather and Pacquiao hereby provide their express consent for USADA to disclose this information in accordance with the reporting requirement outlined above. This obligation shall survive termination of this Agreement.
- 19) Mayweather and Pacquiao understand and acknowledge that USADA does not control and is therefore not responsible for any disciplinary actions that are or may be taken against them

3/11/15
P

by a State Athletic Commission and/or Professional Boxing Federation, Association or Organization prior to the conclusion of the Results Management Period, on the basis of an adverse analytical finding that is disclosed by USADA in accordance with paragraph 18 of this Agreement. This provision shall survive termination of this Agreement.

Results Management Procedures

- 20) USADA shall provide Results Management Services with respect to each test conducted by USADA and with respect to any evidence of an anti-doping rules violation that may come to the attention of USADA. The Results Management Services can take place at any time during or after the term of this Agreement and can be based on test results or any other information that demonstrates an anti-doping rule violation within the meaning of the Code that occurred during the Testing Period or within one year prior to the Testing Period. This obligation shall survive termination of this Agreement.
- 21) Results Management Services shall be consistent with the terms and conditions set forth in the USADA Protocol, except that any hearing requested by any Party hereto shall only be before a single arbitrator selected according to R-11 of the American Arbitration Association Supplementary Procedures for the Arbitration of Olympic Sport Doping Disputes ("AAA Supplementary Procedures"), who shall be from the Pool of American Arbitration Association ("AAA") arbitrators for anti-doping rule violation cases as defined by R-3 of the AAA Supplementary Procedures (USADA Protocol, Annex D). This provision shall survive termination of this Agreement.
- 22) The decision of the single arbitrator identified in the paragraph above shall be final and binding, and there shall be no right of appeal except in the event of manifest error by the arbitrator with regard to his/her application of the relevant anti-doping rules to the facts of the case. An appeal of the arbitrator's decision shall be submitted to the Court of Arbitration for Sport ("CAS") in accordance with sections 17 (a)-(b) of the USADA Protocol. With the exception of the attorney's fees of the respective Parties and subject to the CAS Panel's Final Order, all costs and fees associated with the initiation and adjudication of the CAS appeal shall be borne entirely by the appellant. This provision shall survive termination of this Agreement.
- 23) Arbitration before the AAA in accordance with the terms of the USADA Protocol, as modified herein, shall be the exclusive means of resolving any dispute related to or arising from: this Agreement, any sample collection or testing conduct by USADA or its agents, any analysis by the testing laboratory, any matter related to the TUE or Results Management Services or any other matter involving USADA or any athlete's eligibility pursuant to sport drug testing rules or the terms of this Agreement. USADA shall publicly announce the results of its testing and of the outcome of any requested hearing at the conclusion of the Results Management Services process. The actions and activities described in paragraphs 20 through 23 shall collectively constitute the "Results Management Procedures." This provision shall survive termination of this Agreement.

3/11/15
Dr

Commitment

- 24) Terms of payment and pricing for the Doping Control Services shall be in accordance with Annex A.
- 25) By executing this Master Agreement, Mayweather and Pacquiao agree not to engage in conduct that would undermine the effectiveness of doping control or to allow any person and/or entity under their control to act in a manner to undermine the effectiveness of doping control.
- 26) USADA reserves the right to withdraw from or discontinue doping control if, at any time, USADA determines that conditions or circumstances exist that undermine or threaten to undermine the integrity of the doping control process.
- 27) Mayweather and Pacquiao shall indemnify, defend and hold harmless USADA and its officers, directors, volunteers, agents, attorneys, insurers and employees in regard of all actions, proceedings, losses, claims, demands, liabilities, judgments or damages, costs, expenses (including legal fees), asserted against, imposed on, suffered, or incurred by a Party, arising out of or in connection with any good faith act of USADA or its officers, directors, volunteers, agents, attorneys, insurers and employees, or the good faith performance of any aspect of the Doping Control Services pursuant to this Master Agreement. This obligation shall survive termination of this Agreement.
- 28) Mayweather and Pacquiao may refer to the fact that USADA is conducting an independent drug testing program for them that is consistent with the provisions of the World Anti-Doping Code; however, other than to their representatives and consultants, Mayweather and Pacquiao shall not disclose to any third party the terms of this Master Agreement, including Annexes A, B and C, without the prior written consent of USADA. Furthermore, USADA's trademarks, service marks or trade names may not be used for any purpose without prior written authorization from USADA. USADA shall be given two hours prior notice and a right of approval for any use of USADA's name in any press release, publicity statement, internet posting or other publication. This provision shall survive termination of this Agreement.
- 29) Mayweather, Pacquiao and USADA shall each maintain strict confidentiality in relation to sample collection, sample analysis and Results Management, in accordance with the provisions of the World Anti-Doping Code. This obligation shall survive termination of this Agreement.

Conflict

- 30) If any rule or regulation whatsoever incorporated or referenced herein conflicts in any respect with the terms of this Agreement, this Agreement shall in all such respects control. Such rules and regulations include, but are not limited to: the Code; the USADA Protocol; the WADA Prohibited List; the ISTUE; and the ISTI. Nothing in this provision should be construed to permit a party to engage in any unlawful act pursuant to this Agreement.

3/11/15


Miscellaneous

- 31) All notices, approvals, or requests in connection with this Master Agreement except for administrative requirements under this Master Agreement shall be sent in writing to:

John Frothingham
USADA Chief Operating Officer
United States Anti-Doping Agency
5555 Tech Center Drive, Suite 200
Colorado Springs, CO 80919
Tel: 719-785-2004
Email: jfrothingham@usada.org

USADA's point of contact for all administrative requirements under this Master Agreement shall be sent in writing to:

Andrew K. Morrison
USADA Director of Sport Testing and Resources Division
United States Anti-Doping Agency
5555 Tech Center Drive, Suite 200
Colorado Springs, CO 80919
Tel: 719-785-2036
Email: amorrison@usada.org

The corresponding point(s) of contact for Mayweather and Pacquiao shall be:

For Mayweather:

Name: LEONARD ELLERBE
Title/Role: CEO MAYWEATHER PROMOTIONS
Street: [REDACTED]
City, State, Zip: [REDACTED]
Phone: [REDACTED]
Email: [REDACTED]

For Pacquiao:

Name: MICHAEL KONZ
Title/Role: Advisor
Street: [REDACTED]
City, State, Zip: [REDACTED]
Phone: [REDACTED]
Email: [REDACTED]

- 32) Nothing in this Master Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities on any person or entity (including, without limitation, any employees of the Parties) other than the Parties to this Agreement or their respective successors or

3/11/15
[Signature]



permitted assigns, except that it is expressly agreed by USADA, Mayweather and Pacquiao that any State Athletic Commission, Professional Boxing Federation, Association or Organization or other sanctioning body may take appropriate legal action to enforce paragraph 6 of this Agreement in order to uphold any sanction imposed by USADA through the Results Management Procedures to prevent an athlete who has been declared ineligible for an anti-doping rule violation from participating in a competition held under its jurisdiction. This provision shall survive termination of this Agreement.

- 33) Any claims, disputes and other matters in question arising out of, or relating to, this Master Agreement, or the breach thereof, if unable to be resolved following good faith efforts to resolve the matter between the Parties, shall be first submitted to mutually agreed non-binding mediation by a mediator appointed by the AAA who is not connected with either Party. The mediation shall take place in Colorado Springs, Colorado, or at a mutually agreed upon site. In the event mediation is not successful in resolving the claims, disputes, or other matters in question, the Parties agree to submit the claims, disputes and other matters in question arising out of or related to this Master Agreement to final and binding arbitration before a single arbitrator selected according to R-11 of the AAA Supplementary Procedures from the Pool of American Arbitration Association arbitrators for anti-doping rule violation cases as defined by R-3 of the AAA Supplementary Procedures. The prevailing Party in arbitration shall be entitled to its reasonable costs and attorneys' fees. Any such arbitration will be held in the United States. This obligation shall survive termination of this Agreement.
- 34) This Master Agreement shall be governed by, and construed in accordance with, the laws of the State of Colorado, excluding any conflict of laws provisions. This provision shall survive termination of this Agreement.
- 35) This Master Agreement, including Annexes A, B and C, represents the entire agreement between USADA, Mayweather and Pacquiao concerning doping control. Any modification to this Master Agreement must be in writing and signed by all Parties in order to be effective.
- 36) No provision of this Master Agreement shall be waived except by agreement in writing signed by the waiving Party. A waiver of any term or provision of this Master Agreement shall not be construed as a waiver of any other term or provision. This provision shall survive termination of this Agreement.
- 37) This Master Agreement, including Annexes A, B and C, may be amended, altered or revoked at any time in whole or in part only through a written instrument setting forth such changes signed by all Parties to this Agreement.
- 38) This Master Agreement may be terminated at any time without cause on ten (10) days written notice by USADA. The termination of this Master Agreement shall be without prejudice to the rights and obligations of any Party as of the date of termination.

3/11/15
[Signature]

39) By executing this Master Agreement, all Parties agree that any prior agreements between USADA, Mayweather and Pacquiao or any of them for the purposes of Doping Control Services for the May 2, 2015, Competition will be terminated.




IN WITNESS THEREOF, the Parties hereto have executed this Master Agreement through their duly authorized representatives as of the day first above written.

<p>Signed on behalf of: USADA</p> <p>By:  _____</p> <p>Name: John Frothingham Title: Chief Operating Officer Date: <u>March 11, 2015</u></p>	
<p>Floyd Mayweather</p> <p>By: _____</p> <p>Name: Floyd Mayweather Date: _____</p>	<p>Manny Pacquiao</p> <p>By:  _____</p> <p>Name: Manny Pacquiao Date: <u>3-11-15</u></p>

mk

39) By executing this Master Agreement, all Parties agree that any prior agreements between USADA, Mayweather and Pacquiao or any of them for the purposes of Doping Control Services for the May 2, 2015, Competition will be terminated.

IN WITNESS THEREOF, the Parties hereto have executed this Master Agreement through their duly authorized representatives as of the day first above written.

<p>Signed on behalf of: USADA</p> <p>By: </p> <p>Name: John Frothingham Title: Chief Operating Officer Date: <u>March 11, 2015</u></p>	
<p>Floyd Mayweather</p> <p>By: </p> <p>Name: Floyd Mayweather Date: <u>3-13-15</u></p>	<p>Manny Pacquiao</p> <p>By: </p> <p>Name: Manny Pacquiao Date: <u>3-11-15</u></p>


mk

Annex A
Testing and Results Management Services Specifications

- 1) During the Testing Period, USADA shall conduct blood and urine tests on Mayweather and Pacquiao as determined by USADA in the sole exercise of USADA's professional judgment and discretion, with the express condition USADA shall make a good-faith effort to ensure that Mayweather and Pacquiao are submitted to an equal number of such no advance notice out-of-competition tests, with the precise number of such tests left to the determination of USADA.
- 2) In the event that additional testing is reasonably required after the Competition to complete follow-up testing and the resolution of any other matters originating during or before the Testing Period, then USADA may collect one or more follow up samples from Mayweather and/or Pacquiao.

3)

Financial and Payment Information



3/11/15
[Signature]

4)

Financial and Payment Information

5)

6)

7)

1/12

3/11/15
[Signature]

Annex B Testing Services Overview

USADA conducts two types of doping control tests: In-Competition ("IC") and Out-of-Competition ("OOC"). IC Testing is conducted at a competition venue, while OOC Testing is no advance notice testing and can occur at any location and at any time. The steps for blood and urine sample collection and processing are similar for both In-Competition and OOC testing.

Sample Collection

A USADA Doping Control Officer ("DCO") will notify an athlete of the need to provide a urine and/or blood sample for doping control. The DCO will accompany the athlete until the sample collection process is completed.

For urine collection:

The first step in the urine collection process is for the athlete to deposit a urine sample of at least 90 milliliters in a plastic collection vessel. The process is observed by a DCO of the same gender as the athlete. The athlete retains possession of the plastic collection vessel until the athlete personally deposits the sample into two specially designed glass transport containers with locking tamper-proof lids, an A and a B bottle. The glass transport containers are known as Berlinger bottles.

After the urine sample is provided, the DCO will ask the athlete to select a sealed sample collection kit. The athlete will have at least three sample collection kits from which to choose. Each kit is pre-sealed with tamper evident tape. Each kit is uniquely numbered and the numbers on the sample collection kit box match with the numbers on both Berlinger bottles and lids.

After selecting a collection kit, the athlete will then open the sample collection kit, pour a prescribed amount of urine into each of the two Berlinger bottles, and seal the bottles. The DCO will check to ensure that the A and B bottles are properly sealed and there is no leakage. The DCO will confirm the urine sample is within the required physiological limits by testing the specific gravity of the sample using the small amount of urine remaining in the collection vessel. All processed samples are sent to a World Anti-Doping Agency ("WADA") accredited laboratory for analysis.

For blood collection:

A Blood Collection Officer ("BCO") will accompany the DCO throughout the blood collection session. A BCO is a qualified phlebotomist who will perform the venipuncture and blood collection procedure. The DCO will process the blood collection session.

An athlete is required to remain in a seated position for a minimum of 20 minutes prior to the blood draw. The DCO will ask the athlete to select individually sealed security and accessory kits. Security kits contain the security bottles used to transport your blood sample to the lab; vacutainer kits include the vacutainer tubes for the collection of blood; and accessory kits contain

3/11/15
A

the butterfly needle, straight needle, and other after-care supplies. Each security kit is uniquely numbered, and this unique number is displayed on the security bottles and on the vacutainer tube labels.

After the 20 minute period, the BCO will begin the blood collection process by selecting an appropriate location on the athlete's arm from where to draw the blood and cleaning the area with a sterile disinfectant swab. The BCO will apply a tourniquet to aid in the collection, and the BCO will perform the venipuncture to draw the blood sample.

A blood draw will be attempted a maximum of three times. During the blood collection process, up to four (4) vacutainer tubes of blood may be collected. The vacutainers are used to collect whole blood and/or serum from the athlete. For any blood collection session, the total volume of blood being collected will be approximately one tablespoon (16mL).

After the relevant vacutainer tubes are filled with blood, the BCO will label each tube with the corresponding sample code number for the security bottles, confirming with the athlete that each tube was labeled appropriately. The DCO will direct the BCO to secure each tube in its respective security bottle and verify that each tube is securely placed within the security bottles. Once the sample(s) are secure with the lid tightly sealed, the DCO and the athlete may check to ensure the bottles are sealed properly by trying to turn the security lids counterclockwise so they do not open. The security bottles are then placed in clear transport bags and sealed for shipment. All processed samples are sent to a World Anti-Doping Agency ("WADA") accredited laboratory for analysis.

Laboratory Analysis

WADA laboratories are equipped with devices to remove the sealed tamper-proof and tamper-evident sample bottle lids without compromising the sample. The chain of custody of each sample is tracked and documented by USADA. Every sample sent to a WADA-accredited laboratory is accompanied by a redacted copy of the Doping Control Official Record ("DCOR") and a Declaration of Use Form, which does not include the athlete's name. The information on the laboratory copy of the DCOR does not indicate the identity of the athlete, so that the identity of the athlete who has provided the sample is completely anonymous to the laboratory.

At the laboratory, all samples are analyzed in accordance with the WADA International Standard for Laboratories ("ISL") (which may be found at <https://www.wada-ama.org/en/resources/laboratories/international-standard-for-laboratories-isl>). The 2015 WADA Prohibited List (which may be found at <https://www.wada-ama.org/en/what-we-do/prohibited-list>) sets forth the prohibited substances and methods which will be prohibited for purposes of in-competition and out-of-competition testing and Results Management Services during the Testing Period and Results Management Period.

If the A sample is reported as adverse, USADA will promptly conduct an internal review to determine whether an applicable TUE has been granted or will be granted or if there is any apparent departure from the ISTI or ISL that caused the adverse analytical finding. If this review does not reveal an applicable TUE or departure, and regardless of whether the adverse analytical finding is for a "Specified Substance" within the meaning of Article 4.2.2 of the Code, or a

3/11/15
[Signature]

prohibited substance other than a Specified Substance, USADA will communicate such finding to the impacted athlete, the non-impacted athlete, the Fight Promoter(s) and the appropriate State Athletic Commission(s) within twenty-four (24) hours of USADA's receipt and review of such notification of the laboratory test results for the A sample. USADA may also report any adverse analytical finding to the appropriate Professional Boxing Federation, Association or Organization. The impacted athlete and the appropriate State Athletic Commission shall be provided laboratory documentation in connection with the testing. The impacted athlete will then be given the opportunity to attend a separate B sample analysis and to be accompanied at that analysis by the representative of their choosing. An athlete's sample is considered to be a positive drug test only if the B sample analysis confirms the laboratory finding from the A sample analysis. In the event of a positive drug test USADA shall report such results in writing to each of the parties that were initially notified of the adverse analytical finding within twenty-four (24) hours of USADA's receipt and review of notification of the B sample confirmation from the laboratory or waiver of the B sample analysis by the impacted athlete. USADA may also report any adverse analytical finding to the appropriate Professional Boxing Federation, Association or Organization.

Review of Test Results

MLC
The laboratory test results must be reviewed by at least two certifying scientists at the WADA-accredited laboratory. Once the laboratory reports the test results the analysis is then thoroughly reviewed internally by USADA's scientific staff. Thereafter, before USADA proceeds with the Results Management process with respect to any sample, the laboratory results are also reviewed by at least three members of the Anti-Doping Review Board (ADRB) which is an independent group of scientists, medical personnel and legal experts who also evaluate the accuracy of the test results. The Results Management process will go forward only after the ADRB reviews the information presented to it which USADA has concluded is evidence of an anti-doping rule violation. Accordingly, every positive drug test result must undergo an exhaustive internal review process before USADA brings the matter forward as a potential anti-doping rule violation.

3/4/15
C

Annex C

Promoter(s) Contact Information for Notification of Adverse Analytical Findings

In accordance with the terms of the Master Agreement, entered into between USADA, Mayweather and Pacquiao on March 11, 2015, this document identifies the point(s) of contact for the Fight Promoter(s) who shall receive notification from USADA in the event of an Adverse Analytical Finding resulting from the Doping Control Services provided by USADA.

It is agreed and accepted by the undersigned, that for purposes of Paragraph 18 of the Master Agreement, the Fight Promoter(s) who shall be notified of an adverse analytical finding are:

Promoter: <u>MAYWEATHER PROMOTIONS</u>	Promoter: <u>TOP RANK INC.</u>
Contact Name: <u>LEONARD ELLERRE</u>	Contact Name: <u>HARRISON WHITMAN</u>
Title/Role: <u>CEO, MAYWEATHER PROMOTIONS</u>	Title/Role: <u>GENERAL COUNSEL</u>
Street: <u>[REDACTED]</u>	Street: <u>[REDACTED]</u>
City, State, Zip: <u>[REDACTED]</u>	City, State, Zip: <u>[REDACTED]</u>
Phone: <u>[REDACTED]</u>	Phone: <u>[REDACTED]</u>
Email: <u>[REDACTED]</u>	Email: <u>[REDACTED]</u>

Signed on behalf of: USADA By: <u>[Signature]</u> Name: John Frothingham Title: Chief Operating Officer Date: <u>MARCH 11, 2015</u>	
Floyd Mayweather By: _____ Name: Floyd Mayweather Date: _____	Manny Pacquiao By: <u>[Signature]</u> Name: Manny Pacquiao Date: <u>3-11-15</u>

Annex C
Promoter(s) Contact Information for Notification of Adverse Analytical Findings

In accordance with the terms of the Master Agreement, entered into between USADA, Mayweather and Pacquiao on March 11, 2015, this document identifies the point(s) of contact for the Fight Promoter(s) who shall receive notification from USADA in the event of an Adverse Analytical Finding resulting from the Doping Control Services provided by USADA.

It is agreed and accepted by the undersigned, that for purposes of Paragraph 18 of the Master Agreement, the Fight Promoter(s) who shall be notified of an adverse analytical finding are:

Promoter: <u>MAYWEATHER PROMOTIONS</u>	Promoter: <u>TOP RANK INC.</u>
Contact Name: <u>LEONARD EWERE</u>	Contact Name: <u>HARRISON WHITMAN</u>
Title/Role: <u>CEO, MAYWEATHER PROMOTIONS</u>	Title/Role: <u>GENERAL COUNSEL</u>
Street: <u>[REDACTED]</u>	Street: <u>[REDACTED]</u>
City, State, Zip: <u>[REDACTED]</u>	City, State, Zip: <u>[REDACTED]</u>
Phone: <u>[REDACTED]</u>	Phone: <u>[REDACTED]</u>
Email: <u>[REDACTED]</u>	Email: <u>[REDACTED]</u>

<p>Signed on behalf of: USADA</p> <p>By: <u>[Signature]</u></p> <p>Name: John Frothingham Title: Chief Operating Officer Date: <u>March 11, 2015</u></p>	
<p>Floyd Mayweather</p> <p>By: <u>[Signature]</u></p> <p>Name: Floyd Mayweather Date: <u>3-13-15</u></p>	<p>Manny Pacquiao</p> <p>By: <u>[Signature]</u></p> <p>Name: Manny Pacquiao Date: <u>3-11-15</u></p>



Preserving the integrity of competition. Inspiring true sport. Protecting the rights of U.S. athletes.

**United States Anti-Doping Agency
Drug Test Summary for
Floyd Mayweather**

Test Date	Collection Type	Specimen Type	Determination
Mar 13, 2015	Out-of-Competition	Blood	Analysis Complete
Mar 13, 2015	Out-of-Competition	Urine	Negative
Mar 18, 2015	Out-of-Competition	Blood	Analysis Complete
Mar 18, 2015	Out-of-Competition	Urine	Negative
Mar 19, 2015	Out-of-Competition	Urine	Negative
Mar 28, 2015	Out-of-Competition	Blood	Analysis Complete
Mar 28, 2015	Out-of-Competition	Urine	Negative
Apr 2, 2015	Out-of-Competition	Blood	Analysis Complete
Apr 2, 2015	Out-of-Competition	Urine	Negative
Apr 10, 2015	Out-of-Competition	Blood	Analysis Complete
Apr 10, 2015	Out-of-Competition	Urine	Negative
Apr 15, 2015	Out-of-Competition	Blood	Analysis Complete
Apr 15, 2015	Out-of-Competition	Urine	Negative
Apr 21, 2015	Out-of-Competition	Blood	Analysis Complete
Apr 21, 2015	Out-of-Competition	Urine	Negative
Apr 27, 2015	Out-of-Competition	Urine	Negative
May 1, 2015	Out-of-Competition	Urine	Negative
May 2, 2015	In-Competition	Blood	Analysis Complete
May 2, 2015	In-Competition	Urine	Negative

In accordance with paragraphs 13 and 14 of the Master Agreement, each of the samples indicated above has been analyzed at a WADA-accredited laboratory (the "Laboratory") in accordance with the WADA International Standard for Laboratories ("ISL"). All samples were also subject to special analysis, including but not limited to Erythropoietin ("EPO"), Carbon Isotope Ratio Mass Spectrometry (CIR/IRMS), Blood Parameters, and Human Growth Hormone ("hGH") analysis. The results of these analyses were reported by the Laboratory to USADA in accordance with the ISL for the presence of prohibited substances and evidence of use of prohibited methods in accordance with the current WADA Prohibited List for out-of-competition testing.

Please be advised that the samples indicated above are subject to use in USADA's longitudinal analysis program, in which even test results that are reported by the Laboratory to USADA as negative may be used to establish that an athlete has used performance enhancing drugs. Further, we may retest or reanalyze any sample in accordance with the applicable rules, and therefore, we may retain all associated data or samples for future reference.

U.S. Anti-Doping Agency

5555 Tech Center Drive, Suite 200, Colorado Springs, CO 80919 | Tel: 719.785.2000 | Fax: 719.785.2028
usada@usada.org | www.usada.org



Preserving the integrity of competition. Inspiring true sport. Protecting the rights of U.S. athletes.

**United States Anti-Doping Agency
Drug Test Summary for
Manny Pacquiao**

Test Date	Test Session Name	Specimen Type	Determination
Mar 14, 2015	Out-of-Competition	Blood	Analysis Complete
Mar 14, 2015	Out-of-Competition	Urine	Negative
Mar 17, 2015	Out-of-Competition	Blood	Analysis Complete
Mar 17, 2015	Out-of-Competition	Urine	Negative
Mar 23, 2015	Out-of-Competition	Urine	Negative
Mar 24, 2015	Out-of-Competition	Blood	Analysis Complete
Mar 24, 2015	Out-of-Competition	Urine	Negative
Apr 1, 2015	Out-of-Competition	Blood	Analysis Complete
Apr 1, 2015	Out-of-Competition	Urine	Negative
Apr 9, 2015	Out-of-Competition	Blood	Analysis Complete
Apr 9, 2015	Out-of-Competition	Urine	Negative
Apr 16, 2015	Out-of-Competition	Blood	Analysis Complete
Apr 16, 2015	Out-of-Competition	Urine	Negative
Apr 22, 2015	Out-of-Competition	Blood	Analysis Complete
Apr 22, 2015	Out-of-Competition	Urine	Negative
Apr 27, 2015	Out-of-Competition	Urine	Negative
May 1, 2015	Out-of-Competition	Urine	Negative
May 2, 2015	In-Competition	Blood	Analysis Complete
May 2, 2015	In-Competition	Urine	Negative

In accordance with paragraphs 13 and 14 of the Master Agreement, each of the samples indicated above has been analyzed at a WADA-accredited laboratory (the "Laboratory") in accordance with the WADA International Standard for Laboratories ("ISL"). All samples were also subject to special analysis, including but not limited to Erythropoietin ("EPO"), Carbon Isotope Ratio Mass Spectrometry (CIR/IRMS), Blood Parameters, and Human Growth Hormone ("hGH") analysis. The results of these analyses were reported by the Laboratory to USADA in accordance with the ISL for the presence of prohibited substances and evidence of use of prohibited methods in accordance with the current WADA Prohibited List for out-of-competition testing.

Please be advised that the samples indicated above are subject to use in USADA's longitudinal analysis program, in which even test results that are reported by the Laboratory to USADA as negative may be used to establish that an athlete has used performance enhancing drugs. Further, we may retest or reanalyze any sample in accordance with the applicable rules, and therefore, we may retain all associated data or samples for future reference.

U.S. Anti-Doping Agency

5555 Tech Center Drive, Suite 200, Colorado Springs, CO 80919 | Tel: 719.785.2000 | Fax: 719.785.2028
usada@usada.org | www.usada.org